Examining data from over 850,000 adults in 38 states—including those that have legalized recreational cannabis—the investigators utilized responses from the Behavioral Risk Factor Surveillance System, a robust, annual health behavior survey administered by the Centers for Disease Control and Prevention. Respondents reported their cannabis and tobacco use frequencies over the preceding 30 days, allowing classification into distinct groups: users of neither substance, those using tobacco only, cannabis only, and those using both concurrently.

Statistical analysis reveals a fascinating trend: while sole tobacco and sole cannabis use remained relatively stable—hovering around 14% and 7%, respectively—the concurrent use of tobacco and cannabis has shown a modest but consistent increase, rising from just over 4% to nearly 5.5%. This uptick in co-use raises significant public health concerns given existing evidence that simultaneous consumption exacerbates risks of dependency and may potentiate adverse health outcomes beyond those observed with either substance alone.

The temporal association of these trends with cannabis legalization is of particular note. Post-legalization, the odds of exclusive cannabis use rose by 88%, and concurrent use with tobacco increased by 44%, albeit with a corresponding 13% decline in tobacco-only use. This suggests a substitution and convergence effect in substance use behaviors. Importantly, these dynamics vary substantially across demographic sectors. Young adults (18–24 years) exhibited the largest increases in cannabis use, exceeding 6%, while notable rises were also documented among older adults aged 65 and above—a demographic traditionally characterized by lower rates of cannabis consumption.

Further dissection illustrates that cannabis use escalated among individuals with at least a high school education, a group previously exhibiting lower recreational cannabis engagement. Concurrently, the prevalence of dual substance use also rose in this more educated cohort. In contrast, tobacco use declined more sharply among women compared to men, illuminating gender-specific trajectories in response to policy shifts.

Crucially, mental health emerges as a significant modifier of these trends. Adults reporting poor mental health experienced larger increases in cannabis use and concurrent use behaviors, aligning with prior literature linking substance use patterns with psychological distress. Conversely, this group also showed a more pronounced decline in tobacco-only use, hinting at complex substitution dynamics that warrant further mechanistic exploration.

Geographical disparities also underscore the variability in substance use prevalence. States such as Massachusetts reported sole tobacco use as low as 8%, whereas West Virginia observed rates exceeding 26%. Meanwhile, concurrent tobacco and cannabis use ranged widely, from approximately 3% in Utah to 9.5% in Alaska. These observations highlight the contextual influence of local culture, policy environment, and retail accessibility on consumption behaviors.

The introduction of licensed recreational cannabis retail outlets further intensified trends toward increased cannabis and concurrent use. Availability and normalization of cannabis products through these channels likely facilitate higher consumption, amplified by shifts in public perception about cannabis safety. However, despite these associations, causality cannot be definitively established due to the observational nature of the study and intrinsic limitations of the dataset, including reliance on self-reported data and incomplete coverage of all states.

It is worth noting that the data collection tool—the Behavioral Risk Factor Surveillance System—does not capture critical variables such as the method, timing, or frequency of simultaneous substance use, constraining in-depth behavioral analyses. Additionally, the average response rates per state ranged between 44% and 50%, introducing potential nonresponse bias which may skew prevalence estimates.

Despite these constraints, the study contributes substantially to a growing corpus of evidence suggesting that cannabis legalization and expanded retail access transform patterns of substance use. These changes potentially narrow historical disparities in cannabis use by elevating consumption among groups less traditionally inclined to use, rather than reflecting declines among higher-risk populations. This realignment has profound implications for public health surveillance, prevention strategies, and regulatory frameworks.

The authors caution that ongoing policy evolution demanding increased cannabis access intersects with persistent tobacco control measures, presenting a paradox where tobacco use declines even as co-use with cannabis rises. This suggests multifactorial pathways influenced by legal, social, and individual determinants, warranting multidisciplinary investigative approaches to unravel underlying mechanisms.

In conclusion, as states continue to legalize and commercialize recreational cannabis, a vigilant eye must be kept on the intertwined epidemiology of cannabis and tobacco use. Balanced public health responses need to consider the complexities of polysubstance use, the evolving socio-legal landscape, and demographic disparities to mitigate potential increases in dependence and adverse health consequences linked to concurrent substance consumption.

—

Subject of Research: People

Article Title: Associations between recreational cannabis legalisation and disparities in use and co-use of tobacco and cannabis

News Publication Date: 9-Feb-2026

Web References:
– Behavioral Risk Factor Surveillance System (BRFSS): https://www.cdc.gov/brfss/index.html
– DOI of the article: http://dx.doi.org/10.1136/tc-2025-059748

Keywords: Cannabis, Tobacco, Legislation

The scientific community has long grappled with the ambiguous effects of cannabis on the brain, especially when usage begins during the critical periods of adolescence. Previous studies often produced conflicting results, hampered by retrospective data and inconsistent methodologies. This new investigation circumvents these pitfalls by employing a fine-grained longitudinal design that follows subjects through adolescence into young adulthood, capturing subtle cognitive variations that may have otherwise gone undetected. The implications for public health and policy are profound, as the timing and intensity of cannabis exposure emerge as significant determinants of cognitive development trajectories.

Data gathered reveal that adolescent cannabis use does not exert uniform effects across all cognitive domains, suggesting a complex interplay between neurodevelopmental processes and substance exposure. The research team applied advanced neurocognitive assessments sensitive to executive functions like working memory, attention control, and decision-making. Results indicated that early and frequent cannabis use correlates with modest but statistically significant deficits in these areas by the time participants reach their early twenties. This underscores the vulnerability of the adolescent brain, which is still undergoing critical maturation, particularly within the prefrontal cortex and associated neural networks.

Importantly, the study disaggregates cannabis exposure patterns, distinguishing between occasional and heavy use, as well as varying durations of consumption. This granularity allowed researchers to identify dose-dependent relationships linking heavier and prolonged adolescent cannabis use with more pronounced cognitive impairments. Furthermore, the timing of initiation emerged as a critical factor—those who began using cannabis earlier in adolescence showed the greatest deficits in cognitive performance, compared to their peers who started later or abstained altogether.

Neurobiological mechanisms illuminating these cognitive outcomes are discussed extensively in the study. During adolescence, the endocannabinoid system plays a pivotal role in synaptic pruning and neural plasticity, processes essential for optimizing brain circuitry. Exogenous cannabinoids introduced via cannabis may disrupt this endogenous signaling, potentially leading to aberrant neural connectivity and altered synaptic efficiency. These disruptions manifest as attenuated cognitive capacities, particularly in tasks that demand high-order control processes.

The research methodology emphasizes ecological validity and methodological rigor, including frequent assessments and corroborative data from various cognitive tasks and self-reported cannabis use metrics. This longitudinal approach reduces recall bias and enhances the reliability of the findings. Moreover, the study controlled for confounding variables like socioeconomic status, co-occurring substance use, and mental health conditions, strengthening the causal inferences between cannabis exposure and neurocognitive outcomes.

Findings from this research not only confirm concerns voiced by neuroscientists regarding adolescent cannabis exposure but also demand a refined perspective that balances risk awareness with evidence-based policy frameworks. The stratified impact of usage intensity and onset age calls for tailored preventive interventions designed to delay initiation and minimize heavy use during sensitive developmental windows.

In addition to the core cognitive findings, the study explores secondary psychosocial outcomes, revealing how cannabis-related cognitive decline potentially translates into real-world challenges. Impaired executive functions correlate with academic underachievement, weakened occupational prospects, and compromised decision-making, underscoring wider societal implications. This multidimensional impact reinforces the necessity of early educational campaigns and targeted support systems for at-risk youth.

Furthermore, the results inspire intriguing hypotheses about potential reversibility or mitigation of cognitive deficits with cessation or reduced consumption. While the study focuses primarily on young adulthood, it posits trajectories that warrant further exploration into whether cognitive functions stabilize, recover, or continue to decline with ongoing cannabis exposure versus abstinence.

This extensive longitudinal study contributes substantially to the field of addiction science and adolescent development, offering a meticulously detailed empirical foundation for debate among clinicians, educators, policymakers, and neuroscientists. The nuanced findings underscore the complexity of cannabis’ influence on the developing brain and the importance of precision in public health messaging.

The researchers advocate for responsible cannabis policies that consider both the cognitive vulnerabilities identified and the shifting cultural landscape surrounding cannabis legalization globally. Their data-driven argument emphasizes prevention strategies that prioritize delaying initiation and reducing frequency among youth, coupled with ongoing cognitive monitoring in clinical settings.

Overall, Janousch, Grob, Eggenberger, and their team’s research constitutes a landmark advance, transcending previous methodological limitations and answering critical questions about how cannabis exposure during adolescence tangibly shapes cognitive outcomes years later. Their work paves the way for more sophisticated investigations aimed at disentangling genetic, environmental, and developmental factors in substance-related neurocognitive risks.

As cannabis use continues to evolve socio-legally worldwide, this study stands as an essential evidence base for navigating the attendant public health challenges. It invites continued interdisciplinary research to elucidate mechanisms, identify protective factors, and ultimately guide interventions tailored to safeguard youth cognitive development in an era of expanding cannabis accessibility.

Subject of Research:
The longitudinal impact of adolescent cannabis use on cognitive performance in young adulthood.

Article Title:
A Fine-Grained Longitudinal Study of Adolescent Cannabis Use and Its Relation to Cognitive Performance in Young Adulthood

Article References:
Janousch, C., Grob, U., Eggenberger, L. et al. A Fine-Grained Longitudinal Study of Adolescent Cannabis Use and Its Relation to Cognitive Performance in Young Adulthood. Int J Ment Health Addiction (2025). https://doi.org/10.1007/s11469-025-01604-0

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11469-025-01604-0

Understanding outcome expectancies is pivotal to unraveling why individuals choose to engage in cannabis use recreationally. These expectancies represent the mental models users develop regarding the consequences of cannabis consumption, encompassing both positive and negative anticipated effects. Positive expectancies often include relaxation, social facilitation, and enhanced creativity, whereas negative expectancies might highlight fears of cognitive impairment, anxiety, or legal repercussions. The balance between these opposing expectancies can significantly influence the likelihood, frequency, and context of cannabis use.

Pinquart and Scheurle meticulously analyzed a diverse array of studies, employing meta-analytic techniques to quantify the strength and consistency of associations between specific cannabis outcome expectancies and recreational use. Their methodology involved aggregating effect sizes across heterogeneous samples, which spanned age groups, cultural backgrounds, and varying legal statuses regarding cannabis. This approach allowed for a robust, generalizable understanding of prevailing patterns and the reliability of expectancy effects across different population subsets.

One of the salient findings from the meta-analysis is the disproportionately powerful role of positive expectancies in predicting cannabis use. Individuals holding strong beliefs in the euphoric, calming, or social benefits of cannabis are statistically more likely to engage in recreational consumption. This effect was consistent across demographic variables, suggesting a ubiquitous psychological driver. The implication is that cannabis use intervention programs might benefit from directly addressing and modulating these positive expectancies to mitigate potential misuse.

Conversely, negative outcome expectancies demonstrated a more complex relationship with cannabis use. While logically one might predict that stronger negative beliefs deter use, the meta-analysis reveals that in some contexts, the presence of negative expectancies did not correlate strongly with reduced consumption. In some cases, users simultaneously endorsed certain negative expectancies yet continued to use cannabis recreationally. This paradox hints at a nuanced cognitive balancing act where anticipated positive effects overshadow perceived risks, highlighting the intricate interplay between cognition and behavior.

The meta-analysis also explored age and developmental factors, underscoring critical developmental windows where expectancies might exert maximal influence. Adolescents and young adults, navigating identity formation and social integration, often form expectancies heavily influenced by peer norms, media portrayals, and personal experimentation. The research suggests interventions targeting expectancy restructuring during these sensitive periods could have heightened efficacy in shaping healthier behavioral trajectories.

Furthermore, the legal context surrounding cannabis emerged as a moderating factor. In jurisdictions with legalized recreational cannabis, positive expectancies tended to be more pronounced, likely fueled by shifting social narratives and reduced stigma. Meanwhile, negative expectancies such as fears of legal consequences diminished, potentially lowering barriers to initial use. This finding underscores the necessity for policymakers and public health officials to monitor how legislative changes impact psychological perceptions and consumption behaviors.

A key technical component of the study is the nuanced dissection of expectancy domains—emotional, cognitive, social, and physiological. Meta-analytic evidence pointed to emotional expectancies, such as anxiety relief and mood enhancement, as particularly predictive of use patterns. Cognitive expectancies, including beliefs about creativity and mental sharpness, also played a crucial role, though findings reveal some heterogeneity. Social expectancies, encompassing anticipated peer acceptance and increased sociability, further solidify their influence, especially among younger users.

Importantly, the analysis acknowledged methodological variability among reviewed studies—differences in measurement instruments, sample heterogeneity, and geographic diversity. Through rigorous sensitivity analyses, Pinquart and Scheurle ensured that their conclusions were not unduly biased by outliers or study design differences. This methodological transparency and robustness reinforce the reliability of their findings and their applicability to diverse real-world settings.

The implications of this meta-analysis for public health and clinical practice are multifaceted. Understanding that positive cannabis expectancies strongly motivate use suggests that psychoeducational interventions should not merely convey risks but must also offer alternative narratives addressing perceived benefits. Cognitive-behavioral frameworks could be harnessed to recalibrate expectancies, fostering more realistic appraisals and informed decision-making among potential users.

Additionally, the findings raise important questions about the role of media and cultural representation in shaping outcome expectancies. As cannabis becomes further normalized in mainstream culture, portrayals often emphasize positive effects, potentially amplifying favorable expectancies and increasing consumption rates. This underscores the need for balanced media messaging that accurately reflects both benefits and risks, helping to cultivate a well-informed public.

From a neuroscientific perspective, these expectancy effects likely interface with reward circuitry and cognitive control networks within the brain. Anticipation of positive outcomes may activate dopaminergic pathways, reinforcing usage behavior, while negative expectancies might engage executive functions implicated in risk evaluation. Future research integrating neuroimaging and expectancy assessment could unravel these mechanistic pathways, deepening understanding of cannabis use initiation and maintenance.

Moreover, the meta-analysis opens avenues for personalized interventions. Individual differences, such as genetic predispositions, psychological traits, and prior experiences, likely modulate the formation and impact of outcome expectancies. Tailoring educational and therapeutic approaches based on these individual profiles could enhance efficacy, moving beyond one-size-fits-all frameworks.

The societal ramifications of these findings are significant, particularly as cannabis laws continue to evolve globally. Policymakers must grapple with balancing access and harm reduction, informed by psychological science elucidating user motivations. Comprehensive public health strategies integrating expectancy-focused education, community engagement, and robust regulation may yield optimal outcomes in managing recreational cannabis use.

In conclusion, the meta-analysis by Pinquart and Scheurle offers an incisive, evidence-based exploration of the pivotal role cannabis outcome expectancies play in shaping recreational use patterns. By synthesizing extensive data, their work illuminates the cognitive underpinnings of use behavior, revealing potent motivational forces and highlighting areas for strategic intervention. As cannabis continues to ascend in societal prominence, such rigorous scientific inquiry will be indispensable in guiding effective policy, education, and clinical practice.

This research epitomizes the dynamic intersection of psychology, public health, and social policy, marking a critical advance in our understanding of cannabis use. The nuanced insights captured within this meta-analysis promise to catalyze future research exploring expectancy modification, neurobiological correlates, and personalized preventive strategies. For a world increasingly engaged in the cannabis conversation, these findings resonate as both timely and transformative.

As cannabis legalization expands and cultural narratives continue to evolve, ongoing research into outcome expectancies will remain central in elucidating how beliefs shape behavior. Ultimately, this work underscores that addressing cognitive expectancies is not merely an academic exercise but a practical, vital component of fostering healthier communities amidst changing drug landscapes.

Subject of Research: Association between cannabis outcome expectancies and recreational cannabis use

Article Title: Association of Cannabis Outcome Expectancies with Recreational Cannabis Use—A Meta-Analysis

Article References:
Pinquart, M., Scheurle, K. Association of Cannabis Outcome Expectancies with Recreational Cannabis Use—A Meta-Analysis. International Journal of Mental Health and Addiction (2025). https://doi.org/10.1007/s11469-025-01590-3

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11469-025-01590-3

Fetal Alcohol Spectrum Disorder is a complex condition resulting from prenatal alcohol exposure, characterized by cognitive, behavioral, and physical impairments. Among the myriad challenges individuals with FASD face, managing substance use disorders poses a particularly formidable hurdle. While many studies have documented increased rates of general substance use in this population, the specific patterns and nuances of cannabis consumption have remained obscure, warranting the detailed investigation presented in this study.

Utilizing a robust cohort of adult subjects diagnosed with FASD, the researchers implemented comprehensive assessments to gauge cannabis usage frequency, dosage, and context of use. The methodology involved structured interviews combined with validated psychometric tools, enabling a nuanced exploration of both the qualitative and quantitative dimensions of cannabis consumption. Their approach allowed the unraveling of complex behavioral patterns associated with cannabis use in this unique population, highlighting both protective and risk factors.

The findings reveal an intriguing dimension of cannabis consumption behavior among adults with FASD. Contrary to prevailing assumptions that cannabis use is primarily recreational or solely for self-medication, the data indicates a heterogeneous spectrum of use motives. Some individuals reported using cannabis to alleviate anxiety, manage sensory overload, and cope with mood dysregulation—symptoms commonly associated with FASD neuropathology. This therapeutic facet of cannabis use underscores the potential for novel intervention strategies tailored to this population’s specific neuropsychological needs.

Notably, the research delineates differential patterns in frequency and quantity of cannabis use compared to non-FASD populations. Adults with FASD tend to consume cannabis in more irregular and episodic bouts, sometimes coinciding with heightened stress periods or social isolation. These episodic patterns contrast with more habitual or daily use frequently observed in the general populace. Understanding these consumption rhythms is imperative for clinicians, as it impacts screening accuracy, risk stratification, and the development of targeted harm reduction frameworks.

The neurocognitive implications of cannabis use in FASD adults were a focal point of the investigation. Cannabis, with its complex interaction with the endocannabinoid system, may exert both attenuating and exacerbating effects on the cognitive deficits inherent in FASD. The study discusses how cannabis cannabinoids influence synaptic plasticity, neurotransmitter regulation, and neural connectivity, all of which are already compromised in FASD. This biochemical interplay renders cannabis a double-edged sword—offering symptomatic relief while potentially deepening neurocognitive impairments or psychiatric comorbidities.

Furthermore, the researchers emphasize the significance of comorbid mental health disorders in shaping cannabis use trajectories. Anxiety disorders, depression, and ADHD, frequently comorbid with FASD, appear to modulate the motivation for cannabis consumption. This complex interplay suggests that therapeutic cannabis use should be carefully calibrated within a comprehensive mental health treatment plan, aligning psychopharmacological interventions with psychosocial support tailored to this at-risk group.

A fascinating dimension explored in the paper involves the social determinants influencing cannabis use in FASD adults. Socioeconomic status, access to healthcare, peer influences, and stigma were analyzed as critical external variables that mediate substance use behaviors. The study finds that social isolation and limited access to adequate support services heighten vulnerability, creating environments conducive to maladaptive coping mechanisms including cannabis use. This underscores the necessity for integrative social policies and community health programs aimed at mitigating these determinants.

Importantly, the investigation also touches upon the legal landscape surrounding cannabis. Given the evolving status of cannabis legalization globally, adults with FASD inhabit a unique intersection where increased availability collides with neurodevelopmental vulnerabilities. The study posits that policymakers must weigh these factors carefully, integrating safeguards and educational efforts that specifically target at-risk groups to prevent unintended exacerbation of health disparities.

Clinical implications derived from these findings are multifold. Healthcare providers are urged to incorporate detailed substance use histories into routine FASD care protocols, emphasizing cannabis use given its prevalence and neurobehavioral significance. Tailored therapeutic interventions combining behavioral therapies, psychoeducation, and possibly cannabinoid-mediated treatments might emerge as promising avenues, subject to rigorous clinical trials. The potential for cannabinoid-based therapeutics to alleviate refractory symptoms in FASD opens an innovative frontier for translational research.

The study’s multidisciplinary approach, drawing from neuropsychology, addiction medicine, and social epidemiology, exemplifies the type of integrative research necessary to unravel the complexities of cannabis use in neurodevelopmental disorders. This integrative framework bolsters the external validity of the findings, empowering stakeholders across clinical, social, and policy domains to implement evidence-based strategies that are both clinically effective and socially responsible.

While pioneering, the study also acknowledges its limitations, including reliance on self-reported data prone to bias and a cross-sectional design limiting causality inferences. The authors advocate for longitudinal research employing biomarkers and neuroimaging to delineate trajectories of cannabis use and their neurophysiological correlates in FASD populations. Such advancements would deepen understanding and refine interventions aimed at optimizing mental health outcomes.

The potential for integrating artificial intelligence and machine learning in future research is also briefly considered. These technologies could enable sophisticated pattern recognition and predictive modeling, tailoring individualized treatment plans for adults with FASD and cannabis use. Leveraging big data analytics could harness vast and varied datasets, generating hypotheses and translational pathways previously unattainable.

From a societal perspective, the study calls attention to the urgent need for public education campaigns addressing the unique risks and benefits of cannabis use in neurodevelopmental disability contexts. Sensitizing caregivers, healthcare workers, and community leaders about these nuances promotes informed decision-making and destigmatization, fostering supportive environments conducive to health and well-being.

In sum, the research spearheaded by Reboe-Benjamin and colleagues paves the way for a refined understanding of cannabis use in adults with FASD. By elucidating behavioral patterns, neurocognitive implications, and broader psychosocial determinants, the study charts a roadmap for clinical innovation and policy evolution. As the landscape of cannabis legalization and therapeutic application continues to shift, such targeted investigations remain critical to safeguarding vulnerable populations and harnessing the full spectrum of cannabis’s potential benefits responsibly and effectively.

Subject of Research: Patterns of cannabis use in adults diagnosed with Fetal Alcohol Spectrum Disorder (FASD) and its neurobehavioral, clinical, and social implications.

Article Title: Patterns of Cannabis Use in Adults with Fetal Alcohol Spectrum Disorder (FASD)

Article References:
Reboe-Benjamin, M., DesRoches, A., Reid, D. et al. Patterns of Cannabis Use in Adults with Fetal Alcohol Spectrum Disorder (FASD). Int J Ment Health Addiction (2025). https://doi.org/10.1007/s11469-025-01546-7

Image Credits: AI Generated